Reduced expression in tumor cells is likely due to their proliferation contributing to AAV vector genome loss.108 GB models with higher GFAP expression in and around the tumor, such as GL261 and 005, were more susceptible to this therapeutic strategy than CT-2A, which exhibit lower GFAP expression. This evidence concerns the gene GFAP and neoplasm.